These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38433502)

  • 21. [Testosterone Undecanoate Pills improves insulin resistance in type-2 diabetes men with hypogonadism].
    DI HJ; Fan YF; Zhang HF; Liu KM; Liu C
    Zhonghua Nan Ke Xue; 2017 Jun; 23(6):517-521. PubMed ID: 29722943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).
    Jones TH; Arver S; Behre HM; Buvat J; Meuleman E; Moncada I; Morales AM; Volterrani M; Yellowlees A; Howell JD; Channer KS;
    Diabetes Care; 2011 Apr; 34(4):828-37. PubMed ID: 21386088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism).
    Saad F
    Adv Exp Med Biol; 2017; 1043():527-558. PubMed ID: 29224109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
    Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
    Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.
    Dhindsa S; Ghanim H; Batra M; Kuhadiya ND; Abuaysheh S; Sandhu S; Green K; Makdissi A; Hejna J; Chaudhuri A; Punyanitya M; Dandona P
    Diabetes Care; 2016 Jan; 39(1):82-91. PubMed ID: 26622051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups.
    Ramachandran S; Hackett GI; Strange RC
    Andrology; 2020 Sep; 8(5):1222-1232. PubMed ID: 32384175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is hypoandrogenemia a component of metabolic syndrome in males?
    Singh SK; Goyal R; Pratyush DD
    Exp Clin Endocrinol Diabetes; 2011 Jan; 119(1):30-5. PubMed ID: 20690073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters.
    Dias JP; Shardell MD; Carlson OD; Melvin D; Caturegli G; Ferrucci L; Chia CW; Egan JM; Basaria S
    Andrology; 2017 Jan; 5(1):31-40. PubMed ID: 27792869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
    Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
    Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Testosterone Undecanoate on Sexual Functions, Glycaemic Parameters, and Cardiovascular Risk Factors in Hpogonadal Men with Type 2 Diabetes Mellitus.
    Gandhi R; Kumar PR; Pattanaik SR; Sahoo D
    Indian J Endocrinol Metab; 2022; 26(6):565-574. PubMed ID: 39005512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial.
    Khripun I; Vorobyev S; Belousov I; Kogan M; Zitzmann M
    Aging Male; 2019 Dec; 22(4):241-249. PubMed ID: 30235049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
    Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
    Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.
    Strollo F; Strollo G; Morè M; Magni P; Macchi C; Masini MA; Carucci I; Celotti F; Ruscica M; Gentile S
    Aging Male; 2013 Jun; 16(2):33-7. PubMed ID: 23517433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.